Clinical Trial Update: Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ARV-110 in combination with Abiraterone for Metastatic Castration-Resistant Prostate Cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ARV-110 (ARV-110)
• Abiraterone (abiraterone)

Snippet

Sponsor: Arvinas Androgen Receptor, Inc. | Conditions: Prostate Cancer Metastatic | Phase 1 | Status: COMPLETED